Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.
Fiche publication
Date publication
juin 2023
Journal
Advances in therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
de Pouvourville G, Rossignol P, Boussahoua M, Chevalier J, Gabb PD, Poulnais R, Verboux D, Rao N, Sörstadius E, Garcia Sanchez JJ
Lien Pubmed
Résumé
Gliflozins have historically been indicated for type 2 diabetes in France. However, their efficacy has recently been demonstrated in heart failure and chronic kidney disease (CKD), with positive recommendations by Haute Autorité de Santé for gliflozin therapies in these indications. The study objective was to investigate the 5-year budget impact associated with the introduction of gliflozins in addition to standard therapy in people with CKD and elevated albuminuria, regardless of diabetes status, from the perspective of the French healthcare system.
Mots clés
Budget impact analysis, Chronic kidney disease, End-stage kidney disease, SGLT2 inhibitors
Référence
Adv Ther. 2023 06 21;: